Here are four takeaways from the study:
1. Researches assessed one of the three most common p53 mutations in colorectal cancer (mutp53 R248Q), and exchanged an Arginine for a Glutamine in mice with the disease.
2. They found ablating the mutant gene slowed tumor growth and invasiveness by 50 percent.
3. The researchers also found mutant p53 binds and activates to Stat3, a key tumor promoter, leading to poor outcomes in both mice and humans.
4. “We discovered that in p53-mediated colorectal cancer driven by the most common mutant form of p53, there is an exploitable tumor dependence on continued expression of the mutant protein for the tumors to thrive. Our data suggest that this and similar p53 mutants represent actionable drug targets responsive to treatment by removal,” the authors concluded.
Click here to read the full study.
More articles on gastroenterology:
Van Wert Health expands GI presence through $45M project — 3 insights
Exact Sciences breaks ground on corporate headquarters site — 6 insights
Treatment alerts increase patient outcomes — 4 study insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
